Bradykinin |
رقم الكتالوجGC35548
One-Click Copy Product Info
|
براديكينين هو ببتيد نشط يتم إنشاؤه بواسطة نظام kallikrein-kinin
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 58-82-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Bradykinin is a potent vasodilator peptide that exerts the vasodilatory action through stimulation of specific endothelial B2 receptors, thereby causing the release of prostacyclin, NO, and Endothelium-derived hyperpolarization factor[1]. Bradykinin is associated with the pathological physiological processes accompanying tissue damage and inflammation, and has been used as a regulator in studies on pain and hyperalgesia[2].
In vitro, Bradykinin treatment at 1µM for 16 hours significantly enhanced cell invasion and migration of SW480 cells, and stimulated the activation of ERK1/2 and the production of IL-6 in SW480 cells[3]. Treatment with 1 µM Bradykinin for 24 hours significantly increased the expression of tissue factor and plasminogen activator inhibitor-1 (PAI-1) at both mRNA and protein levels in rat aortic endothelial cells (RAEC)[4]. The treatment with Bradykinin (0.001µM) for 24 hours significantly reduced the senescence of cultured bovine aortic endothelial cells induced by 25μM H2O2, which was manifested by the complete inhibition of the increase in the number of senescent cells and a remarkable decrease in the level of the senescence-associated cell cycle protein p21[5].
In vivo, Bradykinin treatment via intraperitoneal injection at dose of 10mg/kg/day for 5 days significantly reduced the expression of fibrin, inhibiting deep vein thrombosis in mice with inferior cava vein ligation[6]. Intravenous injection of Bradykinin (40µg/kg) in mice can inhibit bronchial contraction caused by acetylcholine (0.5mg/kg; intravenous injection) within 15min[7].
References:
[1] Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans[J]. Circulation, 1997, 95(5): 1115-1118.
[2] Dray A, Perkins M. Bradykinin and inflammatory pain[J]. Trends in neurosciences, 1993, 16(3): 99-104.
[3] Wang G, Ye Y, Zhang X, et al. Bradykinin stimulates IL-6 production and cell invasion in colorectal cancer cells[J]. Oncology reports, 2014, 32(4): 1709-1714.
[4] Kimura S, Tsuji H, Nishimura H, et al. Bradykinin enhances in vitro procoagulant and antifibrinolytic properties of rat vascular endothelial cells[J]. Thrombosis research, 2002, 106(1): 41-50.
[5] Oeseburg H, Iusuf D, van der Harst P, et al. Bradykinin protects against oxidative stress–induced endothelial cell senescence[J]. Hypertension, 2009, 53(2): 417-422.
[6] Dong R, Chen W, Feng W, et al. Exogenous bradykinin inhibits tissue factor induction and deep vein thrombosis via activating the eNOS/phosphoinositide 3-kinase/Akt signaling pathway[J]. Cellular Physiology and Biochemistry, 2015, 37(4): 1592-1606.
[7] Folkerts G, van Heuven-Nolsen D, Nijkamp F P. Bradykinin causes inhibition of methacholine-induced bronchoconstriction in vivo in mice[J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 364(1): 53-58.
| Cell experiment [1]: | |
Cell lines | SW480 cells |
Preparation Method | The SW480 cells were cultured in a DMEM medium containing 10% fetal bovine serum (FBS) at 37°C in a CO2 incubator. A 24-well transwell plate was used, which contained a 8-micron pore polyethylene terephthalate (PET) membrane. The upper layer of the plate was coated with a thin matrix gel. The cells (0.2ml of DMEM per well with 1.0×105 cells) were pretreated with different doses of Bradykinin (0.1, 0.5, and 1µM) and then added to the upper wells. The chemical attractant (20% FBS) was placed in the lower wells. After incubation in the CO2 incubator for 16 hours, the cells passing through the membrane were fixed and stained with eosin. The invasion of cells was observed under a microscope (100× magnification), and the number of invading cells was counted from five random fields. |
Reaction Conditions | 0.1, 0.5, and 1µM; 16h |
Applications | Bradykinin enhanced the invasion of SW480 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | The C57BL/6J mice were randomly divided into 3 groups: the sham operation group, the model group, and the Bradykinin group. Before the operation, the bradykinin group mice were intraperitoneally injected with Bradykinin (10mg/kg/day) for three consecutive days. On the fourth day, after being anesthetized by intraperitoneal injection of 60mg/kg pentobarbital, the midline incision was made to ligate the inferior vena cava (IVC), and the renal vein was dissected at the level of the renal vein. Then, the ligations were performed below the renal vein. After the ligations, the mice continued to receive Bradykinin injection for two more days, and 0.1mg/kg of buprenorphine was administered for analgesia for three days. The other groups of mice were given the same volume of normal saline as a control. The mice in the sham operation group underwent the same surgical procedures except for the ligation of the inferior vena cava. 48 hours later, the mice were euthanized by intraperitoneal injection of 100mg/kg pentobarbital, and the thrombosed inferior vena cava was collected after blood collection, weighed, and measured in length. The samples were frozen or stored for histological analysis. |
Dosage form | 10mg/kg/day for 5 days; i.p. |
Applications | Bradykinin treatment significantly led to a decrease in the expression of fibrin, significantly inhibiting thrombosis in the inferior vena cava of mice. |
References: | |
| Cas No. | 58-82-2 | SDF | |
| Formula | C50H73N15O11 | M.Wt | 1060.21 |
| الذوبان | Water: ≥ 100 mg/mL (94.32 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 943.2 μL | 4.716 mL | 9.4321 mL |
| 5 mM | 188.6 μL | 943.2 μL | 1.8864 mL |
| 10 mM | 94.3 μL | 471.6 μL | 943.2 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)